Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

NCT05299554 is registered in ClinicalTrials.gov with Immedica Pharma AB as lead sponsor.

NCT NCT05299554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05299554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Lead sponsor
Immedica Pharma AB
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2022
Completion date
January 15, 2026
Enrollment
76 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia